Recommendations for the Treatment of Children With Burkitts Lymphoma

What this Trial Is About

This research aims to improve treatment for children with Burkitts Lymphoma across at least 14 Sub Saharan countries, some new to this type of study. It focuses on earlier evaluation of children with stage I and II disease and earlier assessment of treatment response to decide if changes are needed. It also intends to intensify treatment for children with stage IV disease. Starting in 2026, the study will assess adding rituximab to current treatments and compare results with earlier implementations in two specific centers. The study involves observing the ability of treatment centers to follow the established GFA LMB2019 protocol for Burkitts Lymphoma. In two units, an amendment adds four rituximab injections during induction treatment, given on day 1 and day 6 of each induction cycle, depending on the risk group and treatment regimen. Other centers will continue using the original GFA LMB2019 treatment protocol without rituximab. Participants will be monitored over five years to evaluate the number of cases diagnosed with local disease and by stage, the treatments given, follow-up after treatment, and relapse rates. The study will also assess how well therapeutic recommendations are applied. This long-term observation helps understand treatment outcomes and the impact of adding rituximab in selected centers.

Recommendations for the Treatment of Children With Burkitt's Lymphoma